ERG and neoplasm: We then tested an available pharmacological sGC inhibitor on treating TMPRSS2-ERG-positive xenograft tumors and showed that inhibitor treatment alone or in combination with enzalutamide (an AR antagonist) can significantly suppress PCa tumor growth.